Codexis Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Codexis wird ein Gewinn- und Umsatzwachstum von 45.5% bzw. 19.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 47.7% pro Jahr wachsen soll.

Wichtige Informationen

45.5%

Wachstumsrate der Gewinne

47.7%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	18.4%
Wachstumsrate der Einnahmen	19.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	18 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Codexis, Inc.'s (NASDAQ:CDXS) 29% Jump Shows Its Popularity With Investors

Nov 07

After Leaping 26% Codexis, Inc. (NASDAQ:CDXS) Shares Are Not Flying Under The Radar

Jul 26

Is Codexis (NASDAQ:CDXS) Weighed On By Its Debt Load?

Jul 12

Investors Appear Satisfied With Codexis, Inc.'s (NASDAQ:CDXS) Prospects

May 29

Codexis, Inc.'s (NASDAQ:CDXS) Shares Leap 56% Yet They're Still Not Telling The Full Story

Dec 20

Analysts Just Made A Major Revision To Their Codexis, Inc. (NASDAQ:CDXS) Revenue Forecasts

Feb 27

We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn

Feb 25

Is Codexis, Inc. (NASDAQ:CDXS) Trading At A 28% Discount?

Nov 05

Codexis appoints Kevin Norrett as chief operating officer

Oct 03

We Think Codexis (NASDAQ:CDXS) Can Afford To Drive Business Growth

Aug 23

Analysts Have Just Cut Their Codexis, Inc. (NASDAQ:CDXS) Revenue Estimates By 10%

Jul 28

Codexis: Profitability, Return On Capital Are Persistent Headwinds Looking Ahead

Jul 27

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:CDXS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	86	-36	-21	N/A	4
12/31/2025	67	-53	-35	N/A	7
12/31/2024	65	-58	-55	N/A	8
9/30/2024	64	-62	-46	-44	N/A
6/30/2024	61	-76	-49	-47	N/A
3/31/2024	74	-65	-54	-51	N/A
12/31/2023	70	-76	-57	-53	N/A
9/30/2023	74	-82	-41	-37	N/A
6/30/2023	99	-57	-6	-1	N/A
3/31/2023	116	-48	8	13	N/A
12/31/2022	139	-34	3	11	N/A
9/30/2022	133	-31	-7	7	N/A
6/30/2022	135	-19	-29	-13	N/A
3/31/2022	122	-21	-35	-19	N/A
12/31/2021	105	-21	-28	-14	N/A
9/30/2021	101	-15	-26	-16	N/A
6/30/2021	83	-23	-26	-20	N/A
3/31/2021	72	-25	-27	-21	N/A
12/31/2020	69	-24	-20	-16	N/A
9/30/2020	67	-21	-21	-19	N/A
6/30/2020	70	-14	-20	-16	N/A
3/31/2020	68	-14	-15	-11	N/A
12/31/2019	68	-12	-16	-13	N/A
9/30/2019	66	-12	-14	-10	N/A
6/30/2019	61	-14	-12	-10	N/A
3/31/2019	62	-11	-16	-13	N/A
12/31/2018	61	-11	-17	-14	N/A
9/30/2018	66	-9	-8	-6	N/A
6/30/2018	59	-18	N/A	-9	N/A
3/31/2018	56	-20	N/A	-9	N/A
12/31/2017	50	-23	N/A	-9	N/A
9/30/2017	38	-29	N/A	-12	N/A
6/30/2017	43	-18	N/A	-14	N/A
3/31/2017	49	-9	N/A	-6	N/A
12/31/2016	49	-9	N/A	-2	N/A
9/30/2016	50	-5	N/A	0	N/A
6/30/2016	53	-1	N/A	8	N/A
3/31/2016	43	-9	N/A	4	N/A
12/31/2015	42	-8	N/A	0	N/A
9/30/2015	44	-5	N/A	-3	N/A
6/30/2015	34	-15	N/A	-1	N/A
3/31/2015	35	-18	N/A	-1	N/A
12/31/2014	35	-19	N/A	0	N/A
9/30/2014	31	-29	N/A	-9	N/A
6/30/2014	27	-34	N/A	-19	N/A
3/31/2014	28	-38	N/A	-22	N/A
12/31/2013	32	-41	N/A	-23	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CDXS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CDXS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CDXS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CDXSDie Einnahmen des Unternehmens (19.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: CDXSDie Einnahmen des Unternehmens (19.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CDXS in 3 Jahren voraussichtlich hoch sein wird

Codexis Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 11%

Codexis, Inc. Reiterates Earnings Guidance for the Full Year 2024

Codexis, Inc. Reiterates Financial Guidance for the Fiscal 2024

Consensus revenue estimates increase by 12%

Consensus EPS estimates fall by 15%

Recent updates

Codexis, Inc. Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics

Codexis, Inc. Appoints Raymond De Vré to Board of Directors

Codexis, Inc.'s (NASDAQ:CDXS) 29% Jump Shows Its Popularity With Investors

New minor risk - Shareholder dilution

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Codexis, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Codexis, Inc. Announces Executive Changes

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 11%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Codexis, Inc. Reiterates Earnings Guidance for the Full Year 2024

After Leaping 26% Codexis, Inc. (NASDAQ:CDXS) Shares Are Not Flying Under The Radar

Codexis, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Is Codexis (NASDAQ:CDXS) Weighed On By Its Debt Load?

Codexis, Inc. (NasdaqGS:CDXS) entered into an asset purchase agreement to acquire Gene Therapy Assets of Crosswalk Therapeutics.

Investors Appear Satisfied With Codexis, Inc.'s (NASDAQ:CDXS) Prospects

Codexis, Inc. Presents Enzymatic Synthesis Data at TIDES USA Annual Meeting and Launches RNA Ligase Screening and Optimization Services

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Codexis, Inc. Reiterates Financial Guidance for the Fiscal 2024

Codexis, Inc., Annual General Meeting, Jun 11, 2024

Codexis, Inc. to Report Q1, 2024 Results on May 02, 2024

Codexis, Inc. Appoints Carole Cobb to Its Strategic Advisory Board

Consensus revenue estimates increase by 12%

High number of new directors

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Codexis, Inc Appoints Masad Damha, PhD and Jim Lalonde, PhD to Strategic Advisory Board

Codexis, Inc. Announces Not to Stand for Reelection of Jennifer Aaker as Board of Director

Codexis, Inc. announced that it expects to receive $40 million in funding

New major risk - Share price stability

seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting

Codexis, Inc.'s (NASDAQ:CDXS) Shares Leap 56% Yet They're Still Not Telling The Full Story

What Does Codexis, Inc.'s (NASDAQ:CDXS) Share Price Indicate?

Aldevron, LLC entered into an agreement to acquire global exclusive license for Codex® HiCap RNA Polymerase from Codexis, Inc. (NasdaqGS:CDXS).

Is Codexis (NASDAQ:CDXS) In A Good Position To Deliver On Growth Plans?

Consensus EPS estimates fall by 15%

Price target decreased by 17% to US$6.20

Price target increased by 13% to US$8.40

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Codexis, Inc. Reiterates Earnings Guidance for the Year 2023

Codexis, Inc. to Present Update on Eco Synthesis Platform At Tides Europe

Codexis, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Codexis, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Lacklustre Performance Is Driving Codexis, Inc.'s (NASDAQ:CDXS) Low P/S

New minor risk - Share price stability

Calculating The Intrinsic Value Of Codexis, Inc. (NASDAQ:CDXS)

Price target decreased by 7.1% to US$11.14

Codexis, Inc. Unveils Eco Synthesis Platform for Large-Scale RNAi Therapeutics Production at Tides USA

At US$3.41, Is It Time To Put Codexis, Inc. (NASDAQ:CDXS) On Your Watch List?

Price target decreased by 10% to US$11.57

Codexis, Inc. Provides Revenue Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Director & Strategic Advisor exercised options and sold US$159k worth of stock

Director & Strategic Advisor exercised options and sold US$152k worth of stock

Chief Operating Officer recently sold US$77k worth of stock

Consensus revenue estimates decrease by 16%

Price target decreased by 8.8% to US$13.00

Analysts Just Made A Major Revision To Their Codexis, Inc. (NASDAQ:CDXS) Revenue Forecasts

Director & Strategic Advisor notifies of intention to sell stock

We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Codexis, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Codexis, Inc. Announces Cessation of Ross Taylor as Principal Financial and Accounting Officer

Director & Strategic Advisor exercised options and sold US$159k worth of stock

Codexis, Inc. Announces Appointment of Sri Ryali as Chief Financial Officer

Codexis Appoints H. Stewart Parker to Board of Directors

Director & Strategic Advisor exercised options and sold US$132k worth of stock

Director & Strategic Advisor exercised options and sold US$157k worth of stock

Price target decreased to US$14.75

High number of new directors